Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PDE1A | P54750 | 1/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.33 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12438618 | 0.86 | ADRB2 (0.35) | ADRB2PARP1OPRM1OPRD1OPRK1 | |
| SCHEMBL12440345 | 0.83 | ADRB2 (0.34) | ADRB2PARP1OPRM1OPRD1OPRK1 | |
| SCHEMBL14648508 | 0.78 | ADRB2 (0.39) | ADRB2PARP1OPRM1OPRD1OPRK1 | |
| SCHEMBL12440353 | 0.78 | PARP1 (0.38) | ADRB2PARP1OPRM1OPRD1OPRK1 | |
| SCHEMBL12438617 | 0.75 | ADRB2 (0.39) | ADRB2PARP1OPRM1OPRD1OPRK1 | |
| SCHEMBL14648516 | 0.75 | STAT3 (0.40) | ADRB2PARP1OPRM1OPRD1OPRK1 | |
| SCHEMBL12440339 | 0.73 | ADRB2 (0.38) | ADRB2PARP1OPRM1OPRD1OPRK1 | |
| SCHEMBL14648515 | 0.73 | STAT3 (0.40) | ADRB2PARP1OPRM1OPRD1OPRK1 | |
| SCHEMBL13594653 | 0.73 | ADRB2 (0.52) | ADRB2PARP1KDM4EHTTPDE1A | |
| SCHEMBL12438619 | 0.69 | ADRB2 (0.37) | ADRB2PARP1HTTHTR1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2532665-B1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XUANZHU PHARMA CO LTD (CN) | 2016-09-07 | — | — | EP | disclosed |
| US-20160176892-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES | SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD. (CN) | 2016-06-23 | — | — | US | disclosed |
| US-20160176892-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES | SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD. (CN) | 2016-06-23 | — | — | US | disclosed |
| US-9315513-B2 | Benzimidazole derivatives and their pharmaceutical compositions and uses | Xuanzhu Pharma Co., Ltd. (CN) | 2016-04-19 | — | — | US | disclosed |
| US-9315513-B2 | Benzimidazole derivatives and their pharmaceutical compositions and uses | Xuanzhu Pharma Co., Ltd. (CN) | 2016-04-19 | — | — | US | disclosed |
| US-20130023568-A1 | Benzimidazole Derivatives And Their Pharmaceutical Compositions And Uses | Xuanzhu Pharma Co., Ltd. (CN) | 2013-01-24 | — | — | US | disclosed |
| US-20130023568-A1 | Benzimidazole Derivatives And Their Pharmaceutical Compositions And Uses | Xuanzhu Pharma Co., Ltd. (CN) | 2013-01-24 | — | — | US | disclosed |
| EP-2532665-A1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011095057-A1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | 山东轩竹医药科技有限公司 (CN) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176892-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES | F12, HRH2, H1-3 | ADRB2 747/4885PARP1 1226/4885OPRM1 900/4885 |
| US-20130023568-A1 | Benzimidazole Derivatives And Their Pharmaceutical Compositions And Uses | F12, HRH2, H1-3 | ADRB2 747/4885PARP1 1226/4885OPRM1 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.